Yan Leyfman
Aug 6, 2025, 09:22
Yan Leyfman: OASIS 2 Trial – Oral Semaglutide in East Asian Populations
Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared a post on X about a recent article by Takashi Kadowaki et al. published in JAMA Internal Medicine:
“OASIS 2 Trial: Oral Semaglutide in East Asian Populations
In a 68-week RCT of 201 East Asian adults with overweight/obesity (±T2D), oral semaglutide 50 mg led to:
- 14.3% avg weight loss vs. −1.3% with placebo
- 84% achieved ≥5% weight reduction (vs. 17% placebo)
- Improvements in cardiometabolic risk factors
- Safety profile consistent with GLP-1RA class
- GI side effects were common but led to low discontinuation (4.5%)
- Conducted across Japan and South Korea
Takeaway: Oral semaglutide may offer a potent weight management tool in East Asian patients, where obesity-related risk occurs at lower BMIs.”
Title: Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
Authors: Takashi Kadowaki, Line Dam Heftdal, Hae-Jin Ko
Read the Full Article on JAMA Internal Medicine
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 11:59
Aug 9, 2025, 11:37
Aug 9, 2025, 11:29
Aug 9, 2025, 11:12
Aug 9, 2025, 10:59
Aug 9, 2025, 10:52
Aug 9, 2025, 10:47